The Top 5 Biosimilars Articles for the Year of 2018


The Center for Biosimilars® recaps the top news of 2018.


Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the most-read biosimilars articles for the year of 2018.

Number 5: In July, the FDA released its Biosimilar Action Plan.

Number 4: In September, the State of California sued AbbVie for allegedly using kickbacks and nurse ambassadors to boost adalimumab sales.

Number 3: In June, the FDA approved the first pegfilgrastim biosimilar, Fulphila.

Number 2: In April, the United Kingdom’s National Health Service prepared for the arrival of biosimilar adalimumab.

Number 1: In June, the FDA rejected Amgen’s trastuzumab biosimilar, ABP 980.

To read all of these articles and more, visit

Related Videos
GBW 2023 webinar
Fran Gregory, PharmD, MBA
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Ian Henshaw
John Gabrielson
Related Content
© 2023 MJH Life Sciences

All rights reserved.